← SynDRA
GSK-1059615
SynDRA canonical compound SYN0038181 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PIK3CA | PIK3CG |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PI3K inhibitor
- PIK3CG INHIBITOR
Cross-references
Synonyms
- GSK-615
- GSK1059615
- GSK615
- KS-00001CUQ
- CTK8F0346
- HMS3654N17
- BCP02498
- AKOS026750445
- NCGC00346509-01
- FT-0669060
- UNII-07YMO87363
- CHEBI:71955
- RefChem:144501
- DTXCID60164495
- PI3K Inhibitor GSK1059615
- C18H11N3O2S
- QDITZBLZQQZVEE-YBEGLDIGSA-N
- MFCD18074517
- GTPL9826
- orb1305601
- SCHEMBL1805557
- SCHEMBL29351551
- GLXC-06054
- EX-A2223
- BDBM50623161
- NSC801012
- s1360
- AKOS024457937
- CCG-267842
- CS-0187
- EBC-220125
- NSC-801012
- SDCCGSBI-0654260.P002
- NCGC00346509-02
- NCGC00346509-07
- AC-32797
- HY-12036
- MS-25024
- G7301
Look up GSK-1059615 in the interactive SynDRA portal →